Journal of cosmetic dermatology · 2025
Scalp Micropigmentation Is an Effective Treatment for Localized Alopecia: Technical Analysis and a Series of Ten Case Reports.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Qinsi, Sun Mang, Zhang Jiezhi, Zhao Hengguang
Аннотация
BACKGROUND: Scalp micropigmentation (SMP) is emerging for camouflaging localized alopecia, yet standardized protocols and long-term efficacy data remain limited.
AIMS: To evaluate technical parameters, clinical outcomes, and safety of SMP in diverse alopecia subtypes.
METHODS: Ten patients (androgenetic alopecia: n = 6; scarring alopecia: n = 4) underwent a standardized three-session SMP protocol. Technical refinements included zone-specific needle selection (single/triple point), hierarchical pigment deposition (prioritizing thick-haired regions), and randomized distribution to avoid uniformity. Pigment density was incrementally adjusted (30%→70%→100% of natural follicular spacing). Adherence to a zero-bleeding protocol ensured epidermal-upper dermal depth. Outcomes were assessed via visual density score (VDS, 0~10) and patient satisfaction score (PSS, 0~3).
RESULTS: All patients achieved significant cosmetic improvement. Immediate posttreatment VDS averaged 8.7 ± 1.1, with androgenetic cases scoring higher (9.1 ± 0.5). At 6-month follow-up, VDS declined modestly (7.7 ± 1.4), though scarring alopecia showed greater fading (Δ = 1.6 vs. Δ = 0.9 in androgenetic, p = 0.03). Patient satisfaction was high (mean PSS = 2.7/3), with 85.7% of androgenetic cases "very satisfied." Strong correlation existed between VDS and PSS (ρ = 0.91, p < 0.001). No adverse events occurred.
CONCLUSIONS: SMP is a safe, minimally invasive solution for localized alopecia, providing sustained cosmetic improvement. Technical refinements in needle selection, pigment layering, and depth control optimize outcomes. Future studies should focus on long-term pigment retention and expanded cohorts.
AIMS: To evaluate technical parameters, clinical outcomes, and safety of SMP in diverse alopecia subtypes.
METHODS: Ten patients (androgenetic alopecia: n = 6; scarring alopecia: n = 4) underwent a standardized three-session SMP protocol. Technical refinements included zone-specific needle selection (single/triple point), hierarchical pigment deposition (prioritizing thick-haired regions), and randomized distribution to avoid uniformity. Pigment density was incrementally adjusted (30%→70%→100% of natural follicular spacing). Adherence to a zero-bleeding protocol ensured epidermal-upper dermal depth. Outcomes were assessed via visual density score (VDS, 0~10) and patient satisfaction score (PSS, 0~3).
RESULTS: All patients achieved significant cosmetic improvement. Immediate posttreatment VDS averaged 8.7 ± 1.1, with androgenetic cases scoring higher (9.1 ± 0.5). At 6-month follow-up, VDS declined modestly (7.7 ± 1.4), though scarring alopecia showed greater fading (Δ = 1.6 vs. Δ = 0.9 in androgenetic, p = 0.03). Patient satisfaction was high (mean PSS = 2.7/3), with 85.7% of androgenetic cases "very satisfied." Strong correlation existed between VDS and PSS (ρ = 0.91, p < 0.001). No adverse events occurred.
CONCLUSIONS: SMP is a safe, minimally invasive solution for localized alopecia, providing sustained cosmetic improvement. Technical refinements in needle selection, pigment layering, and depth control optimize outcomes. Future studies should focus on long-term pigment retention and expanded cohorts.